A Case of Anaplastic Large Cell Lymphoma Presenting in Leukemic Phase

Rahul Ravilla1*, Appalanaidu Sasapu1, Jeanette M Ramos2 and Konstantinos Arnaoutakis1

1Department of Hematology-Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
2Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA

*Corresponding author: Rahul Ravilla, Department of Hematology-Oncology, University of Arkansas for Medical Sciences, Little Rock, 4301 W. Markham St., Slot #634, Arkansas-72205, AR, USA, Tel: 501-313-9405; Fax: 501-686-6001; E-mail: rravilla@uams.edu

Received date: Sep 22, 2015, Accepted date: Oct 24, 2015, Publication date: Oct 31, 2015

Abstract

Anaplastic lymphoma kinase (ALK) with positive Anaplastic Large Cell Lymphoma (ALCL) is has a distinct entity among the peripheral T-cell lymphomas. With a 5-year survival rate of 70%, it carries one of the best prognoses among peripheral T cell lymphomas. In rare instances, ALK positive ALCL presents in leukemic phase and it has a very poor prognosis with negligible number of cases reporting a survival rate of beyond one year. Following Case study as a research technique, the researchers tried to discuss about a patient affected by ALK positive ALCL in leukemic phase, associated with t (2;5)(p23;q35). The patient reported the clinic with a three week history of breathlessness, fever, diarrhoea, and axillary lymphadenopathy. His condition deteriorated in spite of rapid initiation of chemotherapy, and he succumbed to the high tumor burden. The study concludes that early diagnosis and institution of treatment is important in this regard. As this is a rare medical condition, with negligible alternative solutions, the present study underlines the need for further research in this area, emphasizing the need for newer therapies. It particularly stresses the need to examine the association of EBV and ALCL, with a specific reference to ALK-negative ALCL.

Keywords: ALK positive; Anaplastic large cell lymphoma; Leukemic presentation; EBV

Introduction

Anaplastic large cell lymphoma (ALCL) is a relatively rare type of neoplasm, comprising 3% of the adult onset Non-Hodgkin Lymphoma (NHL) and 10-15% of pediatric NHL cases. It has unique immunohistochemistry (IHC), staining positive for CD30, a marker for Hodgkin's lymphoma along with co-expression of T-cell markers [1]. A subset (40-60%) of ALCL cases have translocation t(2;5)(p23;q35), resulting in formation of Nucleophosmin-Anaplastic lymphoma kinase (NPM-ALK) protein, a trans-membrane tyrosine kinase receptor [2]. Other less common translocations involving ALK gene in cases of ALCL include t(1;2), t(2;3), t(2;17), t(2;19), t(2;22), t(2;X) and inv(2) [3].

ALK positive ALCL has a number of histological variants, but the majority present as the classic/common variant characterized by eccentric horseshoe-shaped nuclei containing "hallmark cells". ALK positive ALCL tends to affect children and young adults with higher male predilection. It carries a good prognosis with five year survival rate of more than 80% even in advanced stage [4]. Rarely ALCL presents in leukemic phase and its true incidence is unknown. The presence of high number of atypical lymphocytes in peripheral blood along with presence of T cell markers make it difficult to differentiate from T-cell leukemia. Epstein-Barr virus (EBV) is a known risk factor for several types of lymphoma but was not shown associated with ALK positive ALCL. We report an unusual case of a patient with ALK-positive ALCL presenting in leukemic phase, who had a history of infectious mononucleosis.

Case

A 31-year-old Caucasian man presented to an outside hospital with a three week history of breathlessness, fever, diarrhoea, and axillary lymphadenopathy. He was diagnosed with infectious mononucleosis 4 years ago. His white cell count on presentation was 15 K/uL. He was started on doxycycline for possible tick borne illness. Imaging with whole body CT scan showed diffuse lymphadenopathy on either side of diaphragm. His White cell count rapidly worsened to 85 K/uL. For suspected leukemia, he was started on hydroxyl urea and allopurinol and transferred to our facility.

His blood counts on arrival to our center showed White cell count 97 K/uL, hemoglobin 12.7 g/dL, platelets 128 K/uL, serum lactate 10 mg/dL and Beta-2 microglobulin 12 mg/dl. His peripheral blood smear showed leukocytosis including neutrophilia and a population of pleomorphic atypical cells, comprising 17% of leukocytes (Figure 1). Flow cytometry on peripheral blood and bone marrow showed an atypical population that expressed bright CD45 and co-expressed CD2, CD56, HLA-DR, CD13, and dim CD4. Bone marrow biopsy showed 50% cellularity. Large, atypical cells were observed in a blood clot adjacent to the biopsy and less frequently in the bone marrow biopsy. IHC stains demonstrated that the tumor cells were positive for CD30 and ALK and were distributed in a sinusoidal pattern in the bone marrow (Figure 2). These cells were negative for CD20, CD3, CD8, and EBER (EBV ISH stain). Interphase FISH demonstrated that 28% of cells had t(2;5)(p23;q35).

He developed multi-organ failure requiring ventilator support and dialysis. We administered one cycle of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to the patient. Unfortunately he succumbed to the illness shortly after finishing this chemotherapy.
studied. More than half of the reported cases have complex karyotype. Our patient had typical translocation t(2; 5) with no additional abnormalities.

International Prognostic Index (IPI) is used to assess the prognosis for NHL and is based on age (>60 years), number of extra-nodal sites (>1), LDH level (above normal), disease stage (III/IV), and Eastern Cooperative Oncology Group (ECOG) performance status (PS 2-4) [7]. Our patient has 4 of these risk factors, which usually carries a 5-year survival rate of 25-33%. The overall 5-year survival rate varies from 90% (IPI 0-1) to 39% (IPI ≥2) [8]. Other predictors for poor prognosis include beta-2 microglobulin level >3 mg/dL and bone marrow involvement as found in our case.

Rapid white blood cell count elevation and clinical deterioration, as seen in this case, is a cause for early initiation of treatment. Even though CHOP based regimens remain the standard of treatment for ALK positive ALCL, especially in North America, these regimens have a poor response rate in leukemic presentation of ALCL. Most of the other regimens, including ESHAP (Etoposide, Methyl prednisone, Cytarabine, Cisplatin) and ICE (Ifosfamide, carboplatin, Etoposide) are generally used in relapsed cases. With Brentuximab Vedotin (CD30 antibody-drug conjugate ) approved for relapsed or treatment resistant ALCL cases [9], there are ongoing trials evaluating effectiveness of this agent when combined with CHOP regimen for induction [10]. Also showing promise is crizotinib, an ALK inhibitor initially approved for ALK positive non-small cell lung cancer and now in phase 3 clinical trials for ALK positive ALCL with phase 2 studies showing great response rates [11]. We hope that newer therapeutic agents will improve the remission and overall survival rates.

Conclusion

We conclude that leukemic presentation of ALK positive ALCL is a rare condition with very unfavorable prognosis. Considering its fulminant course, early diagnosis and institution of treatment is important. Even though CHOP based regimen is effective in usual presentation, leukemic phase has poorer outcomes. Due to rarity of condition the effectiveness of alternate regimens is debatable and there is need for further studies for newer therapies. The association of EBV and ALCL, especially ALK-negative ALCL, warrants further investigation.

Conflicts of Interest

The authors have no conflicts of interest to disclose.

References

1. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, et al. (1985) The expression of the Hodgkin's disease associated antigen ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66: 848-858.
2. Morris SW, Kirstein MN, Valentine MB, Dittmer K, Shapiro DN, et al. (1995) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 267: 316-317.
3. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8: 11-23.
4. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, et al. (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93: 3913-3921.
5. Nguyen JT, Condron MR, Nguyen ND, De J, Medeiros LJ, et al. (2009) Anaplastic large cell lymphoma in leukemic phase: extraordinarily high white blood cell count. Pathol Int 59: 345-353.

6. Herling M, Rassidakis GZ, Jones D, Schmitt-Graeff A, Sarris AH, et al. (2004) Absence of epstein-barr virus in anaplastic large cell lymphoma: A study of 64 cases classified according to world health organization criteria. Hum Pathol 35: 455-459.

7. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, et al. (2010) Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 28: 2373-2380.

8. Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26: 4124-4130.

9. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, et al. (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30: 2190-2196.

10. http://clinicaltrials.gov/show/NCT01777152.

11. Farina F, Stasia A, Ceccon M, Redaelli S, Mologni L, et al. (2013) High Response Rates To Crizotinib In Advanced, Chemo resistant ALK+ Lymphoma Patients. ASH Annual Meeting Abstracts 122: 368.